Skip to content
Screener

Travere Therapeutics, Inc. TVTX Income from Discontinued Ops

Discontinued — last reported Q2 '25

Income from Discontinued Ops at other companies

Synopsys logo
SynopsysSNPS
$0+100%
Dollar Tree logo
Dollar TreeDLTR
$0.00-100%
Corteva logo
CortevaCTVA
-$10M-400%
KEE
Keel InfrastructureKEEL
-$17.78M-3.5%
Babcock & Wilcox Enterprises logo
Babcock & Wilcox EnterprisesBW
$0.02+129%
DigitalBridge Group logo
DigitalBridge GroupDBRG
-$5.5M-31.5%

Segments

By segment

See full
Reportable Segment-$500,000.00

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.89B+284%
Enterprise value$5.82B+277%
P/S11×+6.4×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare.

The source filing: Travere Therapeutics, Inc.’s 10-Q, filed August 6, 2025.

Filed
Aug 6, 2025
Fiscal quarter
Q2 FY2025
Calendar quarter
Q2 2025
Accession
0001438533-25-000046
Line itemThree Months Ended June 30, 2025Three Months Ended June 30, 2024Six Months Ended June 30, 2025Six Months Ended June 30, 2024
Per share data
Basic and diluted:
Net loss from continuing operations$(0.14)$(0.90)$(0.61)$(2.66)
Net loss from discontinued operations(0.01)(0.01)
Net loss per common share$(0.14)$(0.91)$(0.61)$(2.67)
Weighted average common shares outstanding88,945,62477,500,24588,652,42877,318,369
Comprehensive loss:
Net loss$(12,755)$(70,409)$(53,981)$(206,470)

Item 1. Financial Statements

FAQ

What is Travere Therapeutics, Inc.'s income from discontinued ops?
Travere Therapeutics, Inc. (TVTX) reported income from discontinued ops of $0.00 in Q2 2025.
How has Travere Therapeutics, Inc.'s income from discontinued ops changed year-over-year?
Travere Therapeutics, Inc.'s income from discontinued ops increased by 100.0% year-over-year, from -$0.01 to $0.00.
What is the long-term trend for Travere Therapeutics, Inc.'s income from discontinued ops?
Over 3 years (2021 to 2024), Travere Therapeutics, Inc.'s income from discontinued ops has grown at a -74.7% compound annual growth rate (CAGR), from $0.62 to -$0.01.
What does income from discontinued ops mean?
Gains or losses from business segments that have been sold, abandoned, or classified as held for sale, reported net of applicable income taxes.

Ask your AI about Travere Therapeutics, Inc.'s income from discontinued ops.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude